Figure 1A. Efficacy Outcomes Stratified by Baseline LDL-C

Primary Composite Endpoint

All Patients _•

Baseline LDL-C <70 mg/dL

I

Baseline LDL-C 2:70 mg/dl ₀

I

I

HR (95°/o Cl}

0.85 (0.79-0.92)
0.80 (0.60-1.07)

0.86 (0.79-0.92)

Pinteraction

0.65

0.4 1.0 2.5
Secondary Composite Endpoint

All Patients

I

I

•

0.80 (0.73-0.88)

Baseline LDL-C <70 mg/dL Baseline LDL-C 2:70 mg/dl

0.70 (0.48-1.01)

I
-a-

I

0.81 (0.73-0.89)

I

I
0.44

OA 1D 2.5

Evolocumab better Placebo better

9%
8%
7%

Directory: bitstream -> 10044
bitstream -> Present state of the area
10044 -> A new Method to Determine Dispersive Surface Energy Site Distributions by Inverse Gas Chromatography
10044 -> A case study of japanese language teaching
10044 -> Palaeomagnetic evidence for the persistence or recurrence of geomagnetic main field anomalies in the South Atlantic
10044 -> Blair W. McPhee, a, b, c
10044 -> Inattention blindness in surgery
10044 -> Archie Hughes-Hallett, mrcs
10044 -> Intraoperative ultrasound overlay in robot assisted partial nephrectomy
10044 -> Micronutrient supplementation augments anti-mycobacterial immune responses in tst reactive household contacts
10044 -> Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy 2